Diapride M2 HV Tablet

Drug | Tablet

Type 2 diabetes mellitus with inadequate control on dual therapy, especially for post-meal (postprandial) glucose spikes

Glimepiride increases insulin secretion from the pancreas. Metformin reduces liver glucose production and improves insulin sensitivity. Voglibose inhibits intestinal alpha-glucosidase enzymes, delaying carbohydrate absorption and reducing post-meal glucose rise.

Take with the first bite of a main meal or as directed by doctor (voglibose works best with meals). Do not crush/chew sustained-release metformin tablets. Monitor blood glucose; do not skip meals to reduce hypoglycaemia risk.

Hypoglycaemia, nausea, diarrhoea, abdominal pain, flatulence, bloating, dizziness

Hypoglycaemia risk due to glimepiride; treat low sugar with glucose (not sucrose) if on alpha-glucosidase inhibitor. Metformin may rarely cause lactic acidosis; avoid in severe kidney impairment and during dehydration/acute illness; monitor renal function. Voglibose may cause significant gas/diarrhoea; use caution in inflammatory bowel disease, intestinal obstruction, or chronic intestinal disorders.

Alcohol, iodinated contrast media (hold metformin), insulin/other antidiabetics (hypoglycaemia), beta-blockers (mask symptoms), azole antifungals (increase sulfonylurea effect), corticosteroids/diuretics (increase glucose), digestive enzyme preparations/intestinal adsorbents (reduce voglibose effect)